KRAS and lung adenocarcinoma: As an example of this gain in quantitative performance by hybrid-DIA, we analyzed the A549 lung adenocarcinoma cells (ATCC: CCL-185), which harbors an oncogenic G12S mutation in KRAS, where glycine is mutated to serine19.